CL2020000892A1 - Métodos para tratar infecciones bacterianas. - Google Patents

Métodos para tratar infecciones bacterianas.

Info

Publication number
CL2020000892A1
CL2020000892A1 CL2020000892A CL2020000892A CL2020000892A1 CL 2020000892 A1 CL2020000892 A1 CL 2020000892A1 CL 2020000892 A CL2020000892 A CL 2020000892A CL 2020000892 A CL2020000892 A CL 2020000892A CL 2020000892 A1 CL2020000892 A1 CL 2020000892A1
Authority
CL
Chile
Prior art keywords
subject
methods
subjects
transplantation
bacterial infections
Prior art date
Application number
CL2020000892A
Other languages
English (en)
Inventor
Michael N Dudley
Elizabeth Alexander
Jeff Loutit
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000892(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of CL2020000892A1 publication Critical patent/CL2020000892A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODOS PARA TRATAR UNA INFECCIÓN BACTERIANA EN SUJETOS INMUNOCOMPROMETIDOS Y SUJETOS CON UNA O MÁS NEOPLASIAS SUBYACENTES INCLUYEN ADMINISTRAR UNA COMBINACIÓN DE MEROPENEM Y VABORBACTAM AL SUJETO. LOS SUJETOS ADECUADOS A SER TRATADOS PUEDEN INCLUIR UN SUJETO CON UN HISTORIAL DE LEUCEMIA O LINFOMA EN CURSO, UN SUJETO QUE HA TENIDO TRASPLANTE DE ÓRGANOS, TRASPLANTE DE CÉLULAS MADRE, TRASPLANTE DE MÉDULA ÓSEA, O ESPLENECTOMÍA, UN SUJETO QUE RECIBE MEDICAMENTOS INMUNOSUPRESORES, UN SUJETO QUE RECIBE QUIMIOTERAPIA ABLATIVA DE MÉDULA ÓSEA, UN SUJETO CON NEUTROPENIA Y UN SUJETO QUE TIENE O HA TENIDO UNA NEOPLASIA.
CL2020000892A 2017-10-03 2020-04-02 Métodos para tratar infecciones bacterianas. CL2020000892A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US201862657402P 2018-04-13 2018-04-13

Publications (1)

Publication Number Publication Date
CL2020000892A1 true CL2020000892A1 (es) 2020-10-23

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000892A CL2020000892A1 (es) 2017-10-03 2020-04-02 Métodos para tratar infecciones bacterianas.

Country Status (15)

Country Link
US (2) US11376237B2 (es)
EP (1) EP3691652A4 (es)
JP (1) JP2020536092A (es)
KR (1) KR20200066664A (es)
CN (1) CN111432821A (es)
AU (1) AU2018345317A1 (es)
BR (1) BR112020006658A2 (es)
CA (1) CA3078238A1 (es)
CL (1) CL2020000892A1 (es)
JO (1) JOP20200075A1 (es)
MX (1) MX2020003670A (es)
PH (1) PH12020550249A1 (es)
SG (1) SG11202003009QA (es)
TW (2) TW202400146A (es)
WO (1) WO2019070591A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020006658A2 (pt) 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6945452B2 (ja) * 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法
KR20190104385A (ko) * 2017-01-09 2019-09-09 렘펙스 파머수티클스 인코퍼레이티드 세균 감염을 치료하는 방법
BR112020006658A2 (pt) 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas

Also Published As

Publication number Publication date
PH12020550249A1 (en) 2021-02-15
CN111432821A (zh) 2020-07-17
EP3691652A4 (en) 2021-07-07
JOP20200075A1 (ar) 2020-04-30
SG11202003009QA (en) 2020-04-29
TW201922241A (zh) 2019-06-16
TW202400146A (zh) 2024-01-01
MX2020003670A (es) 2020-08-03
US20200297695A1 (en) 2020-09-24
KR20200066664A (ko) 2020-06-10
CA3078238A1 (en) 2019-04-11
JP2020536092A (ja) 2020-12-10
US11376237B2 (en) 2022-07-05
BR112020006658A2 (pt) 2020-09-24
AU2018345317A1 (en) 2020-05-07
EP3691652A1 (en) 2020-08-12
WO2019070591A1 (en) 2019-04-11
US20220288024A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
WO2015168149A3 (en) Sensorineural hair cell differentiation
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
ECSP21026021A (es) Moduladores de la expresión de pnpla3
PH12017501300A1 (en) Novel iodophor composition and methods of use
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
PH12021550122A1 (en) Solubilized apyrases, methods and use
EA202092748A1 (ru) Модуляторы экспрессии apol1
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2021000719A (es) Composicion de microbiota fecal, para su uso en la reduccion de la inflamacion inducida por tratamiento.
CL2020003169A1 (es) Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia
CL2020000892A1 (es) Métodos para tratar infecciones bacterianas.
MX2020000249A (es) Composiciones antimicrobianas efectivas contra bacterias y hongos.
EA201991488A1 (ru) Модуляторы калиевых каналов
UY38472A (es) Moduladores de la expresión de foxp3
CR20210029A (es) MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA